AU2000280405A1 - Targeting cells having mad2 mutation for treatment and/or prevention of disease - Google Patents
Targeting cells having mad2 mutation for treatment and/or prevention of diseaseInfo
- Publication number
- AU2000280405A1 AU2000280405A1 AU2000280405A AU2000280405A AU2000280405A1 AU 2000280405 A1 AU2000280405 A1 AU 2000280405A1 AU 2000280405 A AU2000280405 A AU 2000280405A AU 2000280405 A AU2000280405 A AU 2000280405A AU 2000280405 A1 AU2000280405 A1 AU 2000280405A1
- Authority
- AU
- Australia
- Prior art keywords
- mad2
- mutation
- disease
- prevention
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000006806 disease prevention Effects 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/027462 WO2003044525A1 (en) | 2000-10-03 | 2000-10-03 | Targeting cells having mad2 mutation for treatment and/or prevention of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2000280405A1 true AU2000280405A1 (en) | 2003-06-10 |
Family
ID=21741849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2000280405A Withdrawn AU2000280405A1 (en) | 2000-10-03 | 2000-10-03 | Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| AU78597/00A Abandoned AU7859700A (en) | 2000-10-03 | 2000-10-03 | Targeting cells having MAD2 mutation for treatment and/or prevention of disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU78597/00A Abandoned AU7859700A (en) | 2000-10-03 | 2000-10-03 | Targeting cells having MAD2 mutation for treatment and/or prevention of disease |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1334358A1 (en) |
| JP (1) | JP2005509447A (en) |
| AU (2) | AU2000280405A1 (en) |
| WO (1) | WO2003044525A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2906532B1 (en) * | 2006-09-28 | 2008-12-12 | Biomerieux Sa | NEW OLIGONUCLEOTIDE BRAND |
| BRPI0920297A2 (en) * | 2008-10-24 | 2016-08-02 | Magnachem Int Lab Inc | method for selecting pharmaceutically active compounds and pharmaceutically acceptable compound |
| JPWO2011083830A1 (en) * | 2010-01-06 | 2013-05-16 | 学校法人関西文理総合学園 | Novel anticancer agent and screening method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6591596A (en) * | 1995-08-01 | 1997-02-26 | Sloan-Kettering Institute For Cancer Research | Gene encoding the human homolog of mad2 |
-
2000
- 2000-10-03 WO PCT/US2000/027462 patent/WO2003044525A1/en not_active Ceased
- 2000-10-03 AU AU2000280405A patent/AU2000280405A1/en not_active Withdrawn
- 2000-10-03 AU AU78597/00A patent/AU7859700A/en not_active Abandoned
- 2000-10-03 EP EP00968724A patent/EP1334358A1/en not_active Withdrawn
- 2000-10-03 JP JP2003546104A patent/JP2005509447A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005509447A (en) | 2005-04-14 |
| EP1334358A1 (en) | 2003-08-13 |
| WO2003044525A1 (en) | 2003-05-30 |
| AU7859700A (en) | 2003-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2368794B (en) | Prevention and treatment of amyloidogenic disease | |
| HUP0201205A3 (en) | Prevention and treatment of amyloidogenic disease | |
| AU5714601A (en) | Methods for prevention and treatment of gastrointestinal disorders | |
| HUP0100627A3 (en) | Prevention and treatment of amyloidogenic disease | |
| AU2003290548A8 (en) | Prevention and treatment of synucleinopathic disease | |
| AU7186501A (en) | Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases | |
| AU4541101A (en) | Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders | |
| AU2001251613A1 (en) | Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers | |
| AU2001245295A1 (en) | Methods and compositions for the identification, assessment, prevention and therapy of human cancers | |
| AU9527001A (en) | Treatment of T cell disorders | |
| AUPQ622600A0 (en) | Treatment and/or prevention of ocular pain | |
| IL141211A0 (en) | Prevention and treatment of viral disease | |
| EP1356812A4 (en) | Medicines for treatment and prevention of neurogenic pain | |
| IL138692A0 (en) | Treatment and prevention of vascular disease | |
| AU2001238493A1 (en) | Methods and compositions for the identification, assessment, prevention and therapy of human cancers | |
| AU2000280405A1 (en) | Targeting cells having mad2 mutation for treatment and/or prevention of disease | |
| IL151019A0 (en) | Microcompetition and human disease | |
| EP1317271A4 (en) | Therapeutic and cosmetic uses of heparanases | |
| GB0012186D0 (en) | Treatment of cancer and neurological diseases | |
| AU2001267165A1 (en) | Prevention and treatment of mycoplasma-associated diseases | |
| AU2002222125A1 (en) | Prevention and treatment of tachyphylactic response | |
| AU2001233148A1 (en) | Compositions of polygonum odoratum for prevention and treatment of disease | |
| HUP0302882A3 (en) | Improved specificity in treatment of diseases | |
| AU2001245939A1 (en) | Compositions and methods for the identification, assessment, prevention, and therapy of human cancers | |
| GB0030866D0 (en) | Treatment and prevention of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase | ||
| TH | Corrigenda |
Free format text: IN VOL 17, NO 32, PAGE(S) 11268 UNDER THE HEADING COMPLETE APPLICATIONS FILED - NAME INDEX DELETE ALL REFERENCE TO 2000280405 Free format text: IN VOL 17, NO 46, PAGE(S) 16152 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX DELETE ALL REFERENCE TO 2000280405 Free format text: IN VOL 18, NO 4, PAGE(S) 821 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN, PATENTS CEASED OR EXPIRED - 2000 DELETE ALL REFERENCE TO 2000280405 |